

August 10, 2021

**Result posting of ARGX-113-1804 (2019-000361-21)**

Protocol title            Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia

Protocol number        ARGX-113-1804

Dear Madam/Sir

The ARGX-113-1804 has been prematurely ended. The sponsor has decided to change the clinical development strategy for the above mentioned indication. All ongoing activities have been terminated as of April 30th 2019. No subjects were recruited and no sites were activated, as such no (partial) results are available.

Yours sincerely

DocuSigned by:  
*Adeline Boucher*

 Signer Name: Adeline Boucher  
Signing Reason: I approve this document  
Signing Time: 10-Aug-2021 | 2:41 PM CEST

A5EF217A7BE6458BA44164A812000A64

Adeline Boucher  
Head of Regulatory Affairs – Europe

Together  
We Discover

Belgium  
Industriepark-Zwijnaarde 7  
9052 Zwijnaarde (Gent)

USA  
33 Arch Street, 32nd floor  
Boston, MA 02110

Japan  
2-5-8, Akasaka, Minato-ku  
Tokyo 106-0047

T: +32 9 310 34 00  
ON: BE 0.818.292.196  
IBAN: BE46 7370 2845 9136  
[info@argenx.com](mailto:info@argenx.com) [www.argenx.com](http://www.argenx.com)